Literature DB >> 23544263

Gastric cancer with minimal peritoneal metastasis: is this a sign to give up or to treat more aggressively?

Yasuhiro Kodera1.   

Abstract

Peritoneal metastasis from gastric cancer is often undetectable by routine imaging studies. Even a microscopic metastasis detected only by cytologic examination of the peritoneal washes denotes a dismal prognosis, and surgery is ruled out as futile for patients who turn out to be cytology-positive by staging laparoscopy. On the other hand, recent developments in cancer chemotherapy have improved the outcome of the cytology-positive population to the point where a certain proportion of these patients survive for 5 years through a straightforward strategy of radical surgery followed by chemotherapy. Thus, there is certainly a role for surgeons in patients with minimal peritoneal metastasis, both in clinical practice and in clinical trials where multimodal treatment strategies including surgery are to be explored. Even in this category of patients, surgery in combination with various types of chemotherapy remains the only hope for a cure.

Entities:  

Mesh:

Year:  2013        PMID: 23544263      PMCID: PMC4345710     

Source DB:  PubMed          Journal:  Nagoya J Med Sci        ISSN: 0027-7622            Impact factor:   1.131


  31 in total

1.  The new Japanese Classification of Gastric Carcinoma: Points to be revised.

Authors:  Takashi Aiko; Mitsuru Sasako
Journal:  Gastric Cancer       Date:  1998-12       Impact factor: 7.370

2.  Detection of minimal gastric cancer cells in peritoneal washings by focused microarray analysis with multiple markers: clinical implications.

Authors:  Kazuhiko Mori; Tomohiro Suzuki; Hiroshi Uozaki; Hayao Nakanishi; Tetsuya Ueda; Yoshihiro Matsuno; Yasuhiro Kodera; Hiromi Sakamoto; Nobuko Yamamoto; Mitsuru Sasako; Michio Kaminishi; Hiroki Sasaki
Journal:  Ann Surg Oncol       Date:  2007-02-09       Impact factor: 5.344

Review 3.  A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer.

Authors:  Pierre-Anthony Leake; Roberta Cardoso; Rajini Seevaratnam; Laercio Lourenco; Lucy Helyer; Alyson Mahar; Corwyn Rowsell; Natalie G Coburn
Journal:  Gastric Cancer       Date:  2011-08-02       Impact factor: 7.370

4.  Is Borrmann type IV gastric carcinoma a surgical disease? An old problem revisited with reference to the result of peritoneal washing cytology.

Authors:  Y Kodera; Y Yamamura; S Ito; Y Kanemitsu; Y Shimizu; T Hirai; K Yasui; T Kato
Journal:  J Surg Oncol       Date:  2001-11       Impact factor: 3.454

5.  Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group.

Authors:  A Cuschieri; P Fayers; J Fielding; J Craven; J Bancewicz; V Joypaul; P Cook
Journal:  Lancet       Date:  1996-04-13       Impact factor: 79.321

6.  Prognostic significance of intraperitoneal cancer cells in gastric carcinoma: analysis of real time reverse transcriptase-polymerase chain reaction after 5 years of followup.

Authors:  Yasuhiro Kodera; Hayao Nakanishi; Seiji Ito; Yoshinari Mochizuki; Norifumi Ohashi; Yoshitaka Yamamura; Michitaka Fujiwara; Masahiko Koike; Masae Tatematsu; Akimasa Nakao
Journal:  J Am Coll Surg       Date:  2005-11-18       Impact factor: 6.113

7.  Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.

Authors:  H Ishigami; J Kitayama; S Kaisaki; A Hidemura; M Kato; K Otani; T Kamei; D Soma; H Miyato; H Yamashita; H Nagawa
Journal:  Ann Oncol       Date:  2009-07-15       Impact factor: 32.976

8.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

9.  Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma.

Authors:  Yasuhiro Kodera; Yuichi Ito; Seiji Ito; Norifumi Ohashi; Yoshinari Mochizuki; Yoshitaka Yamamura; Masahiko Koike; Michitaka Fujiwara; Hayao Nakanishi; Akimasa Nakao
Journal:  Hepatogastroenterology       Date:  2007 Apr-May

10.  Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer.

Authors:  Kensei Yamaguchi; Masahiro Tada; Noboru Horikoshi; Toru Otani; Hiroya Takiuchi; Soh Saitoh; Ryunosuke Kanamaru; Yasushi Kasai; Wasaburo Koizumi; Yuh Sakata; Tetsuo Taguchi
Journal:  Gastric Cancer       Date:  2002       Impact factor: 7.370

View more
  6 in total

1.  Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial.

Authors:  Yasuhiro Kodera; Naoto Takahashi; Takaki Yoshikawa; Nobuhiro Takiguchi; Kazumasa Fujitani; Yuichi Ito; Katsufumi Miyamoto; Osamu Takayama; Motohiro Imano; Daisuke Kobayashi; Yumi Miyashita; Satoshi Morita; Junichi Sakamoto
Journal:  Gastric Cancer       Date:  2016-02-15       Impact factor: 7.370

2.  A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial.

Authors:  Naoto Takahashi; Mitsuro Kanda; Takaki Yoshikawa; Nobuhiro Takiguchi; Kazumasa Fujitani; Katsufumi Miyamoto; Yuichi Ito; Osamu Takayama; Motohiro Imano; Norio Mitsumori; Junichi Sakamoto; Satoshi Morita; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2018-03-13       Impact factor: 7.370

3.  Enhanced serum methylated p16 DNAs is associated with the progression of gastric cancer.

Authors:  Yi-Chen Wu; Ping Lv; Jing Han; Jiang-Liu Yu; Xin Zhu; Lian-Lian Hong; Wang-Yu Zhu; Qi-Ming Yu; Xin-Bao Wang; Pei Li; Zhi-Qiang Ling
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

4.  Two-photon images reveal unique texture features for label-free identification of ovarian cancer peritoneal metastases.

Authors:  Dimitra Pouli; Elizabeth M Genega; Travis B Sullivan; Kimberly M Rieger-Christ; Valena Wright; Irene Georgakoudi; Thomas Schnelldorfer
Journal:  Biomed Opt Express       Date:  2019-08-06       Impact factor: 3.562

Review 5.  The value of staging laparoscopy in gastric cancer.

Authors:  Nikolaos Machairas; Petros Charalampoudis; Ernesto P Molmenti; Stylianos Kykalos; Peter Tsaparas; Paraskevas Stamopoulos; Georgios C Sotiropoulos
Journal:  Ann Gastroenterol       Date:  2017-03-16

6.  Diagnostic value of negative enrichment and immune fluorescence in situ hybridization for intraperitoneal free cancer cells of gastric cancer.

Authors:  Anqiang Wang; Zhongwu Li; Qian Wang; Yali Bai; Xin Ji; Tao Fu; Ke Ji; Yanwen Xue; Tingxu Han; Xiaojiang Wu; Ji Zhang; Yingjie Yang; Guobin Xu; Zhaode Bu; Jiafu Ji
Journal:  Chin J Cancer Res       Date:  2019-12       Impact factor: 5.087

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.